Internal Medicine, Endocrinology, Diabetes, & Metabolism · Owosso, MI
NPI
1508218033
Since 2016
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
802 W King St Ste C
Owosso, MI, 48867
Phone (989) 729-4131
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
405 services
Medicare patients, 2024
187
Average age 68
Drug cost, 2024
$2.2M
3,706 prescriptions
Company payments, 2025
$141
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammad Daoud was code 99214 (office e&m - established), 121 times for 86 patients. In total Mohammad Daoud billed 405 services in 10 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 121 | 86 | $64.96 | $7,861 |
| 95251 Test - Miscellaneous | Facility | 90 | 48 | $25.89 | $2,330 |
| 99213 Office E&M - Established | Facility | 88 | 73 | $46.85 | $4,123 |
| 99203 Office E&M - New | Facility | 24 | 24 | $60.54 | $1,453 |
| 99442 Telephone Services | Facility | 19 | 13 | $44.86 | $852 |
| 99204 Office E&M - New | Facility | 13 | 13 | $94.18 | $1,224 |
By year: 2022 $27K for 470 services; 2023 $22K for 439 services; 2024 $20K for 405 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammad Daoud prescribed most often to Medicare patients was Levothyroxine Sodium, with 406 prescriptions and refills. In total Mohammad Daoud wrote 3,706 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 406 | 1,152 | 138 | $5,545 |
| Mounjaro Tirzepatide | 363 | 434 | 48 | $443K |
| Metformin Hcl Generic | 236 | 639 | 78 | $2,294 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 230 | 606 | 97 | $59K |
| Ozempic Semaglutide | 160 | 274 | 48 | $253K |
| Jardiance Empagliflozin | 157 | 367 | 48 | $204K |
| Novolog Flexpen Insulin Aspart | 125 | 310 | 50 | $52K |
| Trulicity Dulaglutide | 96 | 164 | 23 | $156K |
| Metformin Hcl Er Metformin Hcl | 89 | 242 | 41 | $1,145 |
| Humalog Kwikpen U-100 Insulin Lispro | 83 | 253 | 42 | $43K |
| Methimazole Generic | 78 | 216 | 30 | $1,429 |
| Pioglitazone Hcl Generic | 75 | 189 | 23 | $1,227 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 75 | 120 | 14 | $75K |
| Farxiga Dapagliflozin Propanediol | 70 | 151 | 24 | $82K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 66 | 143 | 26 | $7,079 |
Brand drugs: 2,071 claims; generic drugs: 1,192 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammad Daoud $141 ($141 in general payments such as food, travel and fees) from 3 companies. The largest payer was Ascendis Pharma Endocrinology Inc with $97.93.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.